Ischemic Cerebrovascular Disease
Conditions
Interventions
intense dose group:20mg/d rosuvastatin treated within 24 hours by oral or gastric tube is applying in intense rosuvastatin group in 2 weeks .
Conventional dose group:5mg/d rosuvastatin treated within 24 hours by oral or gastric tube is applying in conventional rosuvastatin group in 2 weeks .
Sponsors
The First Affiliated Hospital of Jinan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Adults (>=18 years old) with acute ischemic stroke symptoms durating 3 to 4.5 hours and admitted to intravenous thrombolysis will be studied.
Exclusion criteria
Exclusion criteria: 1. Patients with arterial thrombosis; 2. Patients with history of severe trauma or stroke in the latest 3 months; 3. Suspicious Subachronoid hemorrage; 4. Not artery puncture in the point of hemostasis by compression in the latest 1 week; 5. History of incranial hemorrage; 6. Incranial tumor; atery-venous malformation; aneurysm; 7. Recent incranial or vertebral canal operation; 8. Increasing blood pressure: SBP>=180 mm Hg; DBP>=100 mm Hg; 9. Active hemorrage; 10. Tend to acute bleeding, including platelet counts1.7 or PT>15 S; 13. thrombin inhibitors or Xa factor inhibitor is using or APTTINRplatelet count, ECT and Xa factor activity abnormal; 14. blood glucose 1/3 cerebral hemisphere); 16. mRS>1 before symptoms occurred; 17. allergy to atorvastatin; 18. liver founction abnormal or alanine aminotransferase (ALT) > three-fold the upper limit of normal; 19. history of myopathy or creatine kinase > three-fold the upper limit of normal; 20. gastrointestinal diseases; 21. serious heart, pulmonary or kidney diseases; 22. pregnancy; 23. cancers; 24. participated in other clinical trials within 3 monthes; 25. statin therapied before symptoms occurred.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| primary security outcomes;Secondary safety outcomes;Primary clinical endpoints;Secondary safety endpoints; | — |
Countries
China
Contacts
Public ContactXu Anding
The First Affiliated Hospital of Jinan University
Outcome results
None listed